When submitting an abstract for the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the Online Abstract Submission System, authors will be asked to choose the appropriate category that best describes the scientific content of the abstract. This information will be used as a guide by the members of the Scientific Committee in their review of abstracts. Before making a selection, authors should review the entire list below for the most appropriate abstract category.

Angiogenesis and angiogenesis agents
Animal models
Apoptosis, necrosis, and autophagy
Bioinformatics
Biomarkers
Cancer stem cells
Cell cycle regulators
Cellular responses to therapy
Chemistry
Chemoprevention
Clinical trials
DNA repair and modulation
Drug delivery
Drug design
Drug metabolism, transport, and biodistribution
Drug resistance and modifiers
Drug screening
EGFR/Her2
Epigenetic regulation of tumor immunity
Epigenetic targets
Gene therapies
Genomics, proteomics, and target discovery
Heat shock proteins
Hormonal agents and therapy
Imaging
Immune checkpoints
Immune mechanisms invoked by radiation therapy
Immune modulators
Immune monitoring/clinical correlates
Immune response to therapies
In vitro and in vivo models for targets
MAPK pathways
Metabolism
Metastasis and invasion
Molecular classification of tumors
Monoclonal antibodies
mTOR/PI3-kinase
Natural products
New molecular targets
Novel assay technology
Pediatric-early drug development
Pharmacogenetics, pharmacogenomics, and therapeutic response
Pharmacokinetics and pharmacodynamics
Protein-protein interaction
Radiotherapeutics
RNA and RNA-based technologies and therapies
Signal transduction modulators
Target identification and validation
Therapeutic agents: biological
Therapeutic agents: other
Therapeutic agents: small-molecule kinase inhibitors
Topoisomerase inhibitors
Toxicology
Tubulin-interacting agents
Tumor immunology targets
Tumor microenvironment
Tumor suppressors
Other